Facing up to the prescription opioid crisis

BMJ (Online)

Volumn 343, Issue 7823, 2011, Pages

  Dhalla, Irfan A ^a,b,c,d   Persaud, Navindra ^b,c,e   Juurlink, David N ^a,d,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Sunnybrook Health Sciences Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; METHADONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

CHRONIC PAIN; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG USE; ELECTRONIC MEDICAL RECORD; HUMAN; MORBIDITY; MORTALITY; OPIATE ADDICTION; PATIENT EDUCATION; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES; ARTICLE; CLINICAL PRACTICE; NORTH AMERICA; PAIN;

ANALGESICS, OPIOID; HUMANS; NORTH AMERICA; OPIOID-RELATED DISORDERS; PAIN; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS;

EID: 84857394758     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5142     Document Type: Review

References (23)

1. Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS data brief. www.cdc.gov/nchs/data/databriefs/db22.pdf.
2. Dhalla IA, Mamdani MM, Sivilotti MLA, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181:891-6.
3. Rintoul AC, Dobbin MD, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2011;17:254-9.
4. National Centre for Health Statistics. QuickStats: number of poisoning deaths involving opioid analgesics and other drugs or substances-United States, 1999-2007. MMWR 2010;59:1026. www.cdc.gov/mmwr/index2010.html.
5. United Nations. Report of the International Narcotics Control Board for 2009. www.incb. org/pdf/annual-report/2009/en/AR-09-English.pdf.
6. Spence D. Pain revisited: evidence for opioids. BMJ 2010;340:c2659.
7. Office for National Statistics. Deaths related to drug poisoning, England and Wales. www.statistics.gov.uk/statbase/ssdataset.asp?vlnk=7892.
8. Andersen S, Leikersfeldt G. Management of chronic non-malignant pain. Br J Clin Pract 1996;50:324-30. (Pubitemid 126815413)
9. Noble M, Tregear SJ, Treadwell JR, Schoelles K, Noble M. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Sympt Manage 2008;35:214-28.
10. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147-59.
11. Nüesch E, Rutjes AWS, Husni E, Jüni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009;4:CD003115.
12. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010;170:1968-76.
13. Furlan AD, Reardon R, Weppler C, National Opioid Use Guideline Group. Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ 2010;182:923-30.
14. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health 2009;99:221-7.
15. United States of America v The Purdue Frederick Company Inc. Agreed statement of facts. United States District Court, Western District of Virginia. www.vawd.uscourts.gov/PurdueFrederickCo/Exhibit-B.pdf. Accessed: 2010 Nov 11.
16. United States General Accounting Office. Oxycontin abuse and diversion and efforts to address the problem. 2003. www.gao.gov/new.items/d04110.pdf.
17. US Department of Health and Human Services. Warning letter: Duragesic (fentanyl transdermal system). 2 September, 2004. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/ WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054726. pdf.
18. US Department of Health and Human Services. Warning letter: EMBEDA™ (morphine sulfate and naltrexone hydrochloride) extended release capsules for oral use. 8 October 2009. www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ UCM233236.pdf.
19. Pharmaceutical sales 2010. www.drugs.com/top200.html.
20. Hawton K, Bergen H, Simkin S, Brock A, Griffiths C, Romeri E, et al. Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis. BMJ 2009;338:b2270.
21. Dhalla IA, Mamdani MM, Gomes T, Juurlink DN. Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Can Fam Physician 2011;57:e92-6.
22. Gomes T, Juurlink DN, Dhalla IA, Paterson JM, Mamdani MM. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171:686-93.
23. Soumerai SB, Avorn J. Principles of educational outreach ("academic detailing") to improve clinical decision making. JAMA 1990;263:549.